Visium Asset Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Visium Asset Management’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-2,346	Closed	-$241K	–	216
2016 Q2	$241K	Sell	2,346 -521,750	-100%	-$52.2M	0.02%	305
2016 Q1	$48.1M	Sell	524,096 -110,577	-17%	-$11.8M	0.82%	23
2015 Q4	$91.5M	Sell	634,673 -10,222	-2%	-$1.33M	1.38%	8
2015 Q3	$66.7M	Buy	644,895 +9,895	+2%	+$1.16M	0.91%	18
2015 Q2	$104M	Buy	+635,000	New	+$108M	1.47%	8

Other funds holding SIOX

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ZBI

Ziff Brothers Investments New York $267M AUM 49.36% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Visium Asset Management's SIOX Position: Q3 2016 in Review

Visium Asset Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q3 2016, closing a stake of 2,346 shares — an estimated $241K sold.

Visium Asset Management first reported a position in SIOX in Q2 2015 and held it in 5 quarters. The position peaked at $104M in Q2 2015. 95 funds tracked by Wall St. Rank hold SIOX as of Q3 2016.

Visium Asset Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
Visium Asset Management sold 2,346 Sio Gene Therapies Inc. Common Stock shares in Q3 2016, an estimated $241K.
Visium Asset Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 5 quarters.
Visium Asset Management's Sio Gene Therapies Inc. Common Stock position peaked at $104M in Q2 2015.
95 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q3 2016.

Based on Visium Asset Management's 13F filing for Q3 2016.